Synergistic effects of PTC596 with S63845 and trametinib were to be expected, as PTC596 reduces MCL-1 expression in AML cells and may influence expression of MCL1 inducers including MEK, ERK, AKT, STAT3, and STAT5 [26], while S63845 inhibits MCL1 directly, and trametinib inhibits MEK. Here, MAP2K7 is linked to acute myeloid leukemia.